For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Humacyte Inc (NASDAQ: HUMA) closed at $2.33 in the last session, down -3.72% from day before closing price of $2.42. In other words, the price has decreased by -$3.72 from its previous closing price. On the day, 1.55 million shares were traded. HUMA stock price reached its highest trading level at $2.48 during the session, while it also had its lowest trading level at $2.33.
Ratios:
We take a closer look at HUMA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.28 and its Current Ratio is at 3.68. In the meantime, Its Debt-to-Equity ratio is 2.28 whereas as Long-Term Debt/Eq ratio is at 2.15.
On December 20, 2024, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $12 to $15.
On December 11, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $6.H.C. Wainwright initiated its Buy rating on December 11, 2023, with a $6 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 14 ’25 when Scheessele William John bought 6,493 shares for $1.54 per share. The transaction valued at 9,999 led to the insider holds 22,018 shares of the business.
Sander Dale A. bought 20,000 shares of HUMA for $30,600 on Apr 10 ’25. The CFO and Chief Corp. Deve. Off. now owns 40,600 shares after completing the transaction at $1.53 per share. On Apr 10 ’25, another insider, Parikh Shamik J, who serves as the Chief Medical Officer of the company, bought 7,500 shares for $1.55 each. As a result, the insider paid 11,625 and bolstered with 7,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 361427264 and an Enterprise Value of 343863328. For the stock, the TTM Price-to-Sale (P/S) ratio is 695.06 while its Price-to-Book (P/B) ratio in mrq is 10.03. Its current Enterprise Value per Revenue stands at 665.113 whereas that against EBITDA is -3.314.
Stock Price History:
The Beta on a monthly basis for HUMA is 1.89, which has changed by -0.7209581 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, HUMA has reached a high of $9.79, while it has fallen to a 52-week low of $1.15. The 50-Day Moving Average of the stock is 2.06%, while the 200-Day Moving Average is calculated to be -33.17%.
Shares Statistics:
According to the various share statistics, HUMA traded on average about 4.02M shares per day over the past 3-months and 4070820 shares per day over the past 10 days. A total of 155.12M shares are outstanding, with a floating share count of 125.45M. Insiders hold about 19.13% of the company’s shares, while institutions hold 39.93% stake in the company. Shares short for HUMA as of 1749772800 were 28426146 with a Short Ratio of 7.62, compared to 1747267200 on 30350872. Therefore, it implies a Short% of Shares Outstanding of 28426146 and a Short% of Float of 21.100001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
At present, 3.0 analysts are actively evaluating the performance of Humacyte Inc (HUMA) in the stock market.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.15 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.16 and -$0.53 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is -$0.07, with 3.0 analysts recommending between $0.85 and -$0.56.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $2.34M. There is a high estimate of $3.92M for the next quarter, whereas the lowest estimate is $810k.
Based on 7 analysts’ estimates, the company’s revenue will be $72.95M in the next fiscal year. The high estimate is $293.28M and the low estimate is $27M.
